SAN MATEO, CA -- (MARKET WIRE) -- September 15, 2006 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported phase 1 data indicating that SCV-07 taken orally was safe and led to circulating plasma concentrations similar to those obtained in previous phase 1 studies using a subcutaneous injection of SCV-07. Importantly, SCV-07 taken orally resulted in only 10% plasma level variability between all volunteers in this study, demonstrating highly predictable plasma concentrations after oral dosing of this drug.
